Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue.
Adult
Aged
Animals
Basophils
/ immunology
Biomarkers
Chemokine CCL11
/ immunology
Chemokine CCL24
/ immunology
Eosinophils
/ immunology
Female
GATA3 Transcription Factor
/ immunology
Humans
Immunity, Innate
Macrophages
/ immunology
Male
Mice
Middle Aged
Pulmonary Disease, Chronic Obstructive
/ immunology
Pulmonary Eosinophilia
/ etiology
Smokers
Young Adult
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
15
01
2019
accepted:
06
02
2020
pubmed:
16
2
2020
medline:
17
2
2021
entrez:
16
2
2020
Statut:
epublish
Résumé
Although elevated blood or sputum eosinophils are present in many patients with COPD, uncertainties remain regarding the anatomical distribution pattern of lung-infiltrating eosinophils. Basophils have remained virtually unexplored in COPD. This study mapped tissue-infiltrating eosinophils, basophils and eosinophil-promoting immune mechanisms in COPD-affected lungs.Surgical lung tissue and biopsies from major anatomical compartments were obtained from COPD patients with severity grades Global Initiative for Chronic Obstructive Lung Disease stages I-IV; never-smokers/smokers served as controls. Automated immunohistochemistry and
Identifiants
pubmed: 32060064
pii: 13993003.00110-2019
doi: 10.1183/13993003.00110-2019
pmc: PMC7236868
pii:
doi:
Substances chimiques
Biomarkers
0
Chemokine CCL11
0
Chemokine CCL24
0
GATA3 Transcription Factor
0
GATA3 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0500729
Pays : United Kingdom
Organisme : Department of Health
ID : H039
Pays : United Kingdom
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: P. Jogdand has nothing to disclose. Conflict of interest: P. Siddhuraj has nothing to disclose. Conflict of interest: M. Mori has nothing to disclose. Conflict of interest: C. Sanden has nothing to disclose. Conflict of interest: J. Jönsson has nothing to disclose. Conflict of interest: A.F. Walls has nothing to disclose. Conflict of interest: J. Kearley is an employee of AstraZeneca (formerly MedImmune LLC) and has stock options in AstraZeneca. Conflict of interest: A.A. Humbles was an employee of AstraZeneca (formerly MedImmune LLC) at the time these analyses were conducted. Conflict of interest: R. Kolbeck was an employee of AstraZeneca (formerly MedImmune LLC) at the time these analyses were conducted. Conflict of interest: L. Bjermer has nothing to disclose. Conflict of interest: P. Newbold is an employee of AstraZeneca (formerly MedImmune LLC) and has stock options in AstraZeneca. Conflict of interest: J.S. Erjefält is founder (and stock owner) of Medetect AB, who received funding from AstraZeneca for conducting parts of the present study.
Références
Nat Rev Immunol. 2015 May;15(5):271-82
pubmed: 25882242
Ther Adv Chronic Dis. 2016 Jan;7(1):34-51
pubmed: 26770668
Am J Respir Crit Care Med. 2000 Jun;161(6):2074-85
pubmed: 10852790
Eur Respir J. 2005 Jul;26(1):52-9
pubmed: 15994389
Lancet Respir Med. 2014 Nov;2(11):891-901
pubmed: 25208464
Am J Respir Crit Care Med. 2016 May 1;193(9):965-74
pubmed: 26641631
Lancet Respir Med. 2018 Feb;6(2):117-126
pubmed: 29331313
Nat Immunol. 2016 Jun;17(6):636-45
pubmed: 27111145
Nat Rev Immunol. 2013 Feb;13(2):75-87
pubmed: 23292121
Thorax. 2013 Jun;68(6):521-31
pubmed: 23412435
Annu Rev Pathol. 2009;4:435-59
pubmed: 18954287
Eur Respir J. 2014 Dec;44(6):1697-700
pubmed: 25323230
Am Rev Respir Dis. 1990 Jul;142(1):91-9
pubmed: 2195937
J Immunol. 2017 Apr 15;198(8):3214-3226
pubmed: 28283567
Eur Respir J. 2008 Jan;31(1):70-7
pubmed: 17804442
Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55
pubmed: 22447964
J Allergy Clin Immunol. 1993 Oct;92(4):537-48
pubmed: 8409114
Respir Res. 2019 Jan 18;20(1):14
pubmed: 30658649
Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):879-86
pubmed: 7881686
Nat Immunol. 2016 Jun;17(6):626-35
pubmed: 27111143
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Eur J Immunol. 2016 Dec;46(12):2749-2760
pubmed: 27621211
Immunity. 2015 Mar 17;42(3):566-79
pubmed: 25786179
Nat Immunol. 2001 Jan;2(1):45-50
pubmed: 11135577
Curr Opin Immunol. 2000 Dec;12(6):624-31
pubmed: 11102764
N Engl J Med. 2004 Jun 24;350(26):2645-53
pubmed: 15215480
Curr Opin Immunol. 2014 Dec;31:1-7
pubmed: 25086241
Annu Rev Immunol. 2017 Apr 26;35:53-84
pubmed: 27912316
PLoS One. 2016 Jan 04;11(1):e0145961
pubmed: 26727464
Annu Rev Immunol. 2012;30:647-75
pubmed: 22224763
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
J Allergy Clin Immunol. 2017 Oct;140(4):1181-1184.e7
pubmed: 28506852
Respirology. 2015 May;20(4):667-70
pubmed: 25645275
Allergy. 2013 Sep;68(9):1177-84
pubmed: 23931643
Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10240-5
pubmed: 23733962
Am J Respir Crit Care Med. 2001 Sep 15;164(6):1053-8
pubmed: 11587996
Proc Am Thorac Soc. 2009 Sep 15;6(6):532-4
pubmed: 19741263
J Virol. 2015 Feb;89(3):1564-78
pubmed: 25410867
Histol Histopathol. 2010 Oct;25(10):1341-54
pubmed: 20712018
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13057-13062
pubmed: 30510003
Curr Opin Hematol. 2017 Jan;24(1):9-15
pubmed: 27673511
N Engl J Med. 2017 Oct 26;377(17):1613-1629
pubmed: 28893134
Am J Respir Crit Care Med. 2018 May 1;197(9):1216-1219
pubmed: 29035097
Am J Respir Crit Care Med. 2017 Aug 1;196(3):375-381
pubmed: 28636425
Lancet. 2011 Sep 10;378(9795):1015-26
pubmed: 21907865
Nat Rev Immunol. 2008 Mar;8(3):183-92
pubmed: 18274560